Neuraxpharm Group is on track to achieve organic net sales growth of 10% in 2019, with expected gross sales of €400m ($436m) this year, the firm has disclosed in a business update.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?